140 related articles for article (PubMed ID: 37644877)
1. Association between sodium-glucose cotransporter 2 inhibitors and pancreatic cancer in the Japanese working-age population.
Tanaka Y; Yokoyama S; Nakagawa C; Uno T; Hosomi K
Int J Clin Pharmacol Ther; 2023 Nov; 61(11):492-502. PubMed ID: 37644877
[TBL] [Abstract][Full Text] [Related]
2. Impact of sodium-glucose cotransporter-2 inhibitors on the risk of hip fracture in older patients in Japan using a nationwide administrative claims database: A matched case-control study.
Saito T; Nojiri S; Kasai T; Hiratsuka Y; Ishijima M; Daida H
Geriatr Gerontol Int; 2023 Jun; 23(6):418-425. PubMed ID: 37139826
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Tang H; Yang K; Li X; Song Y; Han J
Pharmacoepidemiol Drug Saf; 2020 Feb; 29(2):161-172. PubMed ID: 32017292
[TBL] [Abstract][Full Text] [Related]
4. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study.
Siao WZ; Lin TK; Huang JY; Tsai CF; Jong GP
Diab Vasc Dis Res; 2022; 19(3):14791641221098168. PubMed ID: 35549730
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
6. The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus.
van Hulten V; Driessen JHM; Starup-Linde JK; Al-Mashhadi ZK; Viggers R; Klungel OH; Souverein PC; Vestergaard P; Stehouwer CDA; van den Bergh JP
Diabetes Obes Metab; 2023 Nov; 25(11):3235-3247. PubMed ID: 37503747
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
Anan G; Kikuchi D; Omae K; Hirose T; Okada K; Mori T
Endocr J; 2023 Nov; 70(11):1103-1107. PubMed ID: 37673640
[TBL] [Abstract][Full Text] [Related]
8. Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan.
Su YC; Shao SC; Lai EC; Lee CN; Hung MJ; Lai CC; Hsu SM; Hung JH
Diabetes Obes Metab; 2021 Sep; 23(9):2067-2076. PubMed ID: 34047442
[TBL] [Abstract][Full Text] [Related]
9. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management.
Xu B; Li S; Kang B; Zhou J
Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study.
Júlíusdóttir YK; Halili A; Coronel R; Folke F; Torp-Pedersen C; Gislason GH; Eroglu TE
Eur Heart J Cardiovasc Pharmacother; 2023 Jul; 9(5):437-443. PubMed ID: 37173284
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors.
Benjamin T; Schumacher C
Pharmacotherapy; 2020 Oct; 40(10):1002-1011. PubMed ID: 32866995
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
[TBL] [Abstract][Full Text] [Related]
13. Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation.
Werkman NCC; Nielen JTH; van den Bergh JPW; Ejskjaer N; Røikjer J; Schaper NC; Rossi B; Klungel O; Vestergaard P; de Vries F; Driessen JHM
Curr Drug Saf; 2021; 16(1):62-72. PubMed ID: 32767909
[TBL] [Abstract][Full Text] [Related]
14. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
[TBL] [Abstract][Full Text] [Related]
15. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
Kashiwagi A; Shoji S; Kosakai Y; Koga T; Asakawa K; Rokuda M
J Diabetes Investig; 2023 Mar; 14(3):404-416. PubMed ID: 36515129
[TBL] [Abstract][Full Text] [Related]
16. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype.
Lim LL; Tan AT; Moses K; Rajadhyaksha V; Chan SP
J Diabetes Complications; 2017 Feb; 31(2):494-503. PubMed ID: 27866701
[TBL] [Abstract][Full Text] [Related]
17. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
Chung MC; Hung PH; Hsiao PJ; Wu LY; Chang CH; Wu MJ; Shieh JJ; Chung CJ
JAMA Netw Open; 2021 Nov; 4(11):e2135353. PubMed ID: 34797368
[TBL] [Abstract][Full Text] [Related]
18. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
Reed JW
Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
[TBL] [Abstract][Full Text] [Related]
19. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
[TBL] [Abstract][Full Text] [Related]
20. Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation.
Kwon CH; Kim YJ; Kim MJ; Cha MJ; Cho MS; Nam GB; Choi KJ; Kim J
Am J Cardiol; 2022 Sep; 178():35-42. PubMed ID: 35810007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
